Tirzepatide vs Semaglutide: A Physician's Side-by-Side Comparison
By Brandon Phillips — May 13, 2026
Tirzepatide vs semaglutide compared by GOAL.MD physicians: weight loss, side effects, dosing, cost, and who each one is right for.
If you're choosing between tirzepatide (the active ingredient in Mounjaro® and Zepbound®) and semaglutide (Ozempic® and Wegovy®), you're looking at the two most effective FDA-approved weight-loss medications ever brought to market. Both work — but they don't work the same way, and they don't work the same way for every patient.
This is the comparison our physicians walk patients through during intake. We've compressed it into one page.
The 30-second answer
- Semaglutide is a single-pathway GLP-1 receptor agonist. Average weight loss in the STEP trials: ~15% of body weight at 68 weeks.
- Tirzepatide is a dual GIP / GLP-1 receptor agonist. Average weight loss in the SURMOUNT-1 trial: ~20.9% of body weight at 72 weeks.
- Tirzepatide produces more weight loss on average. Semaglutide has a longer real-world safety record at weight-loss doses and is sometimes better tolerated by patients sensitive to GI side effects.
- Cost, supply, and prior medication history usually decide which one your physician recommends.
How they actually work
GLP-1 (glucagon-like peptide-1) is a gut hormone your body releases after meals. It tells your pancreas to release insulin, slows how fast food leaves your stomach, and tells your brain you're full.
Semaglutide mimics GLP-1. One receptor, one signal.
Tirzepatide mimics GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is a second gut hormone with overlapping but distinct effects on insulin secretion and fat metabolism. The dual action is the reason tirzepatide produces more weight loss in head-to-head data.
Head-to-head clinical data
| Outcome | Semaglutide 2.4 mg (STEP-1) | Tirzepatide 15 mg (SURMOUNT-1) |
|---|---|---|
| Average body-weight loss | 14.9% | 20.9% |
| % of patients losing ≥5% | 86% | 91% |
| % of patients losing ≥15% | 50% | 73% |
| % of patients losing ≥20% | 32% | 57% |
| Trial length | 68 weeks | 72 weeks |
| Population | Adults with obesity, no diabetes | Adults with obesity, no diabetes |
Both trials excluded patients with type 2 diabetes; weight loss is typically lower in patients with T2D for both medications.
Side effects — what to actually expect
Both medications share the same side-effect profile because they hit the same GLP-1 receptor: nausea, constipation, diarrhea, reflux, fatigue, and reduced appetite. These are most intense in the first 4–8 weeks of any dose increase and almost always improve.
In published trials, GI side effects were slightly more common on tirzepatide at the highest doses, but trial dropout rates were similar (about 7% for each).
Less common but important to know about:
- Gallbladder issues — both can increase risk of gallstones, especially with rapid weight loss.
- Pancreatitis — rare but possible with both.
- Thyroid C-cell tumors — both carry a boxed warning based on rodent studies. Avoid if you have a personal or family history of medullary thyroid carcinoma or MEN-2.
Who tirzepatide is usually right for
- You want the highest probability of significant weight loss.
- You've tried semaglutide and plateaued.
- You have type 2 diabetes alongside excess weight (Mounjaro® indication).
- You can tolerate (or want to push through) slightly stronger GI effects in early titration.
Who semaglutide is usually right for
- You're new to GLP-1s and want to start with a more established medication.
- You have a history of GI sensitivity (IBS, gastroparesis, severe reflux).
- You're targeting moderate weight loss (10–15%) rather than maximal.
- You're cost-sensitive — compounded semaglutide is typically the most accessible GLP-1 option for cash-pay patients.
What we prescribe at GOAL.MD
GOAL.MD is a physician-led telehealth practice. Our intake collects your medical history, current medications, weight history, and goals. Your physician then recommends one of:
- Brand-name access for Wegovy®, Zepbound®, Mounjaro®, or Ozempic® via manufacturer programs (LillyDirect™ / NovoCare).
- Compounded semaglutide or tirzepatide as a treatment cycle.
- GLP-1 Synergy (semaglutide + tirzepatide) for patients with the right clinical profile.
Compare every option on our GLP-1 treatment hub or take the 3-minute intake to see what your physician recommends.
FAQs
Is tirzepatide just a stronger version of semaglutide?
No. Tirzepatide activates a second receptor (GIP) that semaglutide doesn't touch. The dual action is mechanistically different, not just a higher dose.
Can I switch from semaglutide to tirzepatide?
Yes — many patients do, especially if they've plateaued. Your physician will restart titration from a low tirzepatide dose to limit GI side effects.
Is one safer than the other?
Both have similar safety profiles in published trials. Semaglutide has more years of post-marketing surveillance at weight-loss doses simply because it was approved earlier (2021 vs 2023).
Will I regain weight if I stop?
Both. The STEP-4 and SURMOUNT-4 extension trials showed meaningful weight regain after discontinuation for both medications. GLP-1 therapy is most effective as a long-term tool, paired with nutrition and behavior support.
Medically reviewed by Dr. Michael Mimlitz, MD (NPI 1508891870), Chief Physician of GOAL.MD. Physician-supervised telehealth. More at goal.md/blog.